Key Takeaways
- A year of reset, Q4 shows green shoots: FY22 saw the first-ever revenue drop and a 10-point gross margin decline, but Q4 marked a turning point with volume recovery beginning and cost programs taking hold.
- US business deflated by $50 mn, now rebuilding: Price erosion of 10–35% and a volume collapse halved sales, but disruptive competitors have exited and rebids are coming at higher prices.
- Endo's Chestnut Ridge portfolio closes the strategy gap: The acquisition, consolidating from June, adds a broader portfolio beyond acute therapies and is expected to contribute a $25 mn quarterly exit run rate this year.
- Stelis holds promise and overhang: The CDMO business onboarded 12 customers in year one, but the Sputnik inventory ($40 mn sale value) and AmbiVax outcome remain unresolved, putting all Stelis plans on hold.
- What to watch next quarter: Whether the US quarterly run rate actually approaches the $60 mn needed for the $250 mn full-year guide, and any resolution on the Sputnik inventory.
US Business: The Damage and the Rebuild
- Price deflation was severe but selective: Drops ranged from 10% to 35%, concentrated in the acute portfolio where some players dumped inventory and then exited; those players are now gone and rebids are coming at higher prices.
- Volume collapse created an inventory overhang: Volumes dropped by more than half in FY22 while production continued near full annual operating plan, leaving the company sitting on significant inventory that is now being drawn down as volumes return.
- Recovery is already visible: Volume pickup began as early as Q1 FY23, which will improve cash flows dramatically; the company is producing only to demand now, not to estimates.
- Logistics costs are normalizing: Sea freight had spiked from $6,000 to $25,000 per container; air freight is being eliminated except for extraordinary opportunities, and expensive front-end warehousing costs are falling as inventory normalizes.
- Acute therapy dynamics have improved: The number of players has reduced further as those who dumped product exited; prescriptions and market share are returning, and the market has become more attractive.
Arun Kumar: "In the acute therapy, the number of players continue to be few, in which what Strides flourished its strategy, so in the acute whoever dump the product is no more in the market in fact that market has become more attractive for us as a number of players have probably even reduced further."
The Endo Transaction and Portfolio Fix
- The acute-only strategy broke during COVID: Pre-COVID the narrow acute focus worked well, but the pandemic exposed the gaps; the combined Endo and Strides portfolio removes that narrowness as an excuse.
- Chestnut Ridge integration begins June 2022: Some products were taken on as soon as the deal was announced; Chestnut Ridge is expected to have an exit run rate of about $25 mn per quarter this year.
- Launch momentum is back-loaded but real: Bigger product launches from Chestnut Ridge are happening in Q1 and Q2; hormone launches in Q2, controlled substances returning in Q4, and special products like megestrol returning as early as Q1.
- 20-product launch cadence committed: All products are already approved and not dependent on any regulatory inspections or facility inspections; minimum 20 launches per year starting now.
- Puducherry OAI has zero impact: Site changes are done; the OAI does not affect launching already approved products.
Arun Kumar: "What the transaction with Endo has done for us has clearly solved what used to be an acute only strategy, which worked very well for us pre-COVID but COVID clearly exposed the portfolio strategy gaps and now with the combined portfolio that we have from Endo and Strides, we do not have any more excuses on our narrowness of our portfolio..."
Margin Recovery Path
- Gross margins fell 10 points in FY22: US gross margins dropped from roughly 70% to about 60%, driven by price deflation and volume under-absorption.
- No further margin decline expected: Management does not see a drop from current levels, but improvement will not be across the board; the US is expected to settle between 60% and 65% gross margin, with 3–4 points of global gross margin recouped from FY22 losses.
- Getting back to 70% US gross margin is a long haul: The near-term target is the 60–65% range, with full recovery a multi-year effort.
- Cost improvement programs are structural: Initiatives include reducing the complexity of international businesses, cutting the number of subsidiaries, and moving to matrix and functional leadership; these are expected to enable market leadership in several products.
- R&D spend is being cut meaningfully: No need for significant US R&D investments for the next three years; the company will not file 25–30 products annually anymore, only critical products aligned to the new domain strategy.
- Other regulated markets carry stronger EBITDA flow-through: These markets have lower gross margins but no associated SG&A and US costs, so the flow-through margin is stronger; the company is among the top 10 players in Europe in other regulated markets.
Arun Kumar: "I do not see a drop in margins from where we are, but it will not be across the board that we will be able to improve the margins and it is going to take us some time before we get back to our historical 60% gross margin. I mean to be fair US gross margin of 70% and now it is about 60% so getting back to 70% is a long haul and I think somewhere between 60 and 65 we should settle in the US and then kind of recoup at least 3% or 4% of the global gross margins that we have lost in FY2022, and I am quite confident about getting that."
Stelis: CDMO Promise, Sputnik Overhang
- CDMO business had a strong first year: Onboarded 6 customers in year one and another 6 new customers in Q4; the supply book is now in the vicinity of 10 crore for the first years of master service activities.
- The model is differentiated: Stelis does not do small contracts; it does service contracts only with supplies, making it a uniquely different biological CDMO compared to other Indian players.
- Operational breakeven is 12–18 months away: MFA contracts for this year will help operationally break even.
- Sputnik inventory is the unresolved risk: The company is sitting on inventory with a sale value close to $40 mn; dating of stocks is good with 12 months remaining, so no risk for the next 3–4 months, but the next two quarters are critical to find a solution.
- All Stelis plans are on hold: Until a solution for Sputnik is found and there is clarity on AmbiVax, all plans are paused; existing investors have committed an additional $65 mn in capital.
- AmbiVax is progressing: Phase 3 dosing is complete in India; EUA status has been issued by the Government of India; final clinical data submission is expected by mid-June; a booster study across all variants has been applied for.
- EU inspection outcome is positive: Three plants and two blocks were inspected by EU Authorities with great outcomes; formal approvals are expected, and a strong inbound of customers is already visible.
Arun Kumar: "Stelis' CDMO business is unique considering that we do not do small contracts. We do service contracts only with supplies, which makes us a very uniquely different biological CDMO compared to other players in the country..."
Balance Sheet and Cash Flow
- Debt reduction of ₹1,000 crore is the stretched target: Free cash generation is confident to the extent of ₹450 Cr debt reduction even without any minor P&L exits, which are about ₹100–150 Cr.
- Australia payment acceleration helps: Partners have agreed to bring forward payments originally due December 31; funds are expected in H1, 5–7 months early; this is the last payment from that agreement.
- Inventory normalization will release cash: The company expects inventory to be normalized to the extent needed by year-end; it is not filling new stocks until existing stocks are depleted.
- Net debt to EBITDA on pharma will be under 2x by year-end on a run-rate basis, net of investments.
- Capex is modest: About ₹100 Cr per year for the next 2–3 years; plants have large capacities and enough headroom for the next 2–3 years.
- Market exits are freeing resources: The company has exited markets like Canada and parts of Europe where it cannot scale.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| US revenue | Achieve $250 mn guided revenue | FY23 |
| US quarterly run rate | Approach $60 mn per quarter | "Very soon" |
| Product launches | Minimum 20 per year, all already approved | Starting now (FY23) |
| Chestnut Ridge exit run rate | $25 mn per quarter | FY23 |
| Debt reduction | ₹1,000 crore (stretched target); at least ₹450 Cr from free cash | FY23 |
| Net debt to EBITDA (pharma) | Under 2x on run-rate basis | FY23 exit |
| EBITDA margin | 16–20% range | FY23 exit |
| US gross margin | Settle between 60% and 65% | No timeline (long haul) |
| Global gross margin recapture | Recoup 3–4% of gross margins lost in FY22 | No timeline |
| Stelis CDMO operational breakeven | Break even operationally | 12–18 months |
| AmbiVax phase 3 data submission | Submit final clinical data to Government of India | Mid-June 2022 |
| Sputnik inventory solution | Find a solution | Next two quarters (critical) |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Revenue | ₹4.4 cr (US sales), moved from ₹38 cr |
| US business annual guidance | $250 million, expected to be linear through the year |
| Gross margin decline (FY2022) | 10% drop in FY2022 |
| US gross margin | ~60%, down from historical 70% |
| Global gross margin loss (FY2022) | 3% to 4% |
| Operating cost increase (FY2022) | 16% increase in employee and other expenses |
| Reported consolidated EBITDA | ₹46 cr |
| Exceptional items | ₹77 cr, one-time in nature |
| EBITDA margin (Q4 FY22) | ~5% |
| EBITDA margin target (exit FY23) | 16% to 20% range |
| US revenue deflation (FY2022) | $50 million |
| Price erosion range (FY2022) | 10% to 35%, varying by product |
| Debt reduction target | ₹1,000 cr |
| Target exit EBITDA run rate | Under 3x debt-to-EBITDA |
| Net debt-to-EBITDA (pharma, exit run rate) | Under 2x |
| Inventory (Sputnik) | ~$40 million sale value, 12 months shelf life remaining |
| Stelis CDMO customers onboarded | 6 in first year, plus 6 added in Q4 FY22 |
| Stelis supply book | ~₹10 cr for first years of master service activities |
| Products from Endo acquisition | Over 150 |
| Products currently launched | 55 to 60 |
| Planned product launches per year | 20 minimum |
| Chestnut Ridge expected exit run rate | ~$25 million per quarter |
| Other regulated markets performance | Highest quarter in Q4 FY22 |
| Emerging markets sales reps (French Africa) | ~160 |
| Logistics cost improvement expected | 300 bps |
| Shipping container reduction expected | 40% to 50% fewer containers to sell same or more dollars |
| Ibuprofen market share | 28% to 30%, unchanged since COVID |
| Maintenance capex | ~₹100 cr per year for next 2–3 years |
| Australia partner payment | Last payment, due Dec 31, 2022, accelerated to H1 FY23 |